Company Profile
Prelude Therapeutics Stock Price, News & Analysis
- Ticker:
- PRLD
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
4.68 USD (+3.08%)
Close
Last updated: August 6, 2026
279M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, PRLD closed up 3.08% at $4.68. No new same-company headline was identified in the current news window.
Company overview
Precision Oncology Company
Prelude Therapeutics develops medicines for validated cancer targets using selective degradation and mutant-specific inhibition.
PRT12396
PRT12396 selectively inhibits mutant JAK2V617F and is in Phase 1 development for polycythemia vera and myelofibrosis.
PRT13722
PRT13722 is an oral KAT6A degrader intended for estrogen receptor-positive breast cancer and other KAT6A-dependent tumors.
Future catalysts
An IND submission for PRT13722 is expected around mid-2026.
A Phase 1 study of PRT13722 in ER-positive breast cancer is anticipated in the second half of 2026.
Recent news
- 01
Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Source: Prelude Therapeutics
- 02
Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering
Source: Prelude Therapeutics
- 03
- 04
Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer
Source: Prelude Therapeutics
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Prelude Therapeutics (PRLD)?
Prelude Therapeutics (PRLD) most recently closed at 4.68 USD, a +3.08% move versus the previous session.
What is the market cap of Prelude Therapeutics (PRLD)?
Prelude Therapeutics currently has a market capitalization of 279M USD on BioPharmSignal.
What does Prelude Therapeutics do?
Precision Oncology Company Prelude Therapeutics develops medicines for validated cancer targets using selective degradation and mutant-specific inhibition. PRT12396 PRT12396 selectively inhibits mutant JAK2V617F and is in Phase 1 development for polycythemia vera and myelofibrosis. PRT13722 PRT13722 is an oral KAT6A degrader intended for estrogen...
On which exchange is PRLD stock listed?
Prelude Therapeutics (PRLD) is associated with NASDAQ, United States, Biopharma.
What is Precision?
Precision Oncology Company Prelude Therapeutics develops medicines for validated cancer targets using selective degradation and mutant-specific inhibition.
Which conditions is Prelude Therapeutics targeting with Precision?
Prelude Therapeutics is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Prelude Therapeutics describe recent progress with Precision?
An IND submission for PRT13722 is expected around mid-2026. A Phase 1 study of PRT13722 in ER-positive breast cancer is anticipated in the second half of 2026.
What is Oncology?
Precision Oncology Company Prelude Therapeutics develops medicines for validated cancer targets using selective degradation and mutant-specific inhibition.